drugset

drugset / Trial / NCT06003426

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

NCT06003426 ↗

Phase 3 Active not recruiting 1255 enrolled Bristol-Myers Squibb

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.

Timeline

Start: 2023-09-14
Primary completion: 2026-10-06
Completion: 2027-06-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Admilparant	Small molecule	—	—

Indications